Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 6/20 | 0.55 |
| ▸ | RXRA | P19793 | 1/20 | 0.52 |
| ▸ | RXRB | P28702 | 1/20 | 0.52 |
| ▸ | RXRG | P48443 | 1/20 | 0.52 |
| ▸ | HNF4A | P41235 | 1/20 | 0.51 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CTSV | O60911 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.46 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.46 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.45 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.45 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.45 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.45 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5471405 | 0.94 | PTGER1 (0.56) | PTGER1RXRARXRBRXRGHNF4A | |
| SCHEMBL1315389 | 0.90 | PTGER1 (0.49) | PTGER1RXRARXRBRXRGHNF4A | |
| SCHEMBL1639034 | 0.88 | MAOB (0.50) | PTGER1RXRARXRBRXRGALDH1A1 | |
| SCHEMBL1667777 | 0.88 | BCAT2 (0.56) | PTGER1RXRARXRBRXRGMCL1 | |
| SCHEMBL28948616 | 0.88 | PTGER1 (0.49) | PTGER1MCL1CTSVCTSLPTGER4 | |
| SCHEMBL1315583 | 0.88 | CYP11B1 (0.51) | PTGER1ALDH1A1 | |
| SCHEMBL15716510 | 0.87 | ALDH1A1 (0.58) | PTGER1MCL1ALDH1A1CTSVCTSL | |
| SCHEMBL25431505 | 0.87 | ALDH1A1 (0.56) | PTGER1RXRARXRBRXRGALDH1A1 | |
| SCHEMBL1638569 | 0.87 | PTGER1 (0.50) | PTGER1RXRARXRBRXRGALDH1A1 | |
| SCHEMBL7761823 | 0.86 | MEN1 (0.49) | PTGER1MCL1ALDH1A1CTSVCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331720-A1 | MEDIUM- OR MACRO-CYCLIC BENZYL-SUBSTITUTED HETEROCYCLE DERIVATIVES AND THEIR USES AS OREXIN-2 RECEPTOR AGONISTS | OXFORD FINANCE LLC | 2023-10-19 | — | — | US | disclosed |
| US-20230331720-A1 | MEDIUM- OR MACRO-CYCLIC BENZYL-SUBSTITUTED HETEROCYCLE DERIVATIVES AND THEIR USES AS OREXIN-2 RECEPTOR AGONISTS | OXFORD FINANCE LLC | 2023-10-19 | — | — | US | disclosed |
| US-20230331720-A1 | MEDIUM- OR MACRO-CYCLIC BENZYL-SUBSTITUTED HETEROCYCLE DERIVATIVES AND THEIR USES AS OREXIN-2 RECEPTOR AGONISTS | OXFORD FINANCE LLC | 2023-10-19 | — | — | US | disclosed |
| CN-116874428-A | PNPO inhibitor with multiple myeloma resisting effect, and preparation method and application thereof | 南京中医药大学 | 2023-10-13 | — | — | CN | disclosed |
| EP-4208465-A1 | MEDIUM- OR MACRO-CYCLIC BENZYL-SUBSTITUTED HETEROCYCLE DERIVATIVES AND THEIR USES AS OREXIN-2 RECEPTOR AGONISTS | Orexia Therapeutics Limited (GB) | 2023-07-12 | — | — | EP | disclosed |
| WO-2022051583-A1 | MEDIUM- OR MACRO-CYCLIC BENZYL-SUBSTITUTED HETEROCYCLE DERIVATIVES AND THEIR USES AS OREXIN-2 RECEPTOR AGONISTS | OREXIA THERAPEUTICS LIMITED (GB) | 2022-03-10 | — | — | WO | disclosed |
| EP-0778821-A1 | ORTHO-SUBSTITUTED AROMATIC ETHER COMPOUNDS AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS FOR PAIN RELIEF | ZENECA LIMITED (GB) | 1997-06-18 | — | — | EP | disclosed |
| WO-1996006822-A1 | ORTHO-SUBSTITUTED AROMATIC ETHER COMPOUNDS AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS FOR PAIN RELIEF | ZENECA LIMITED (GB) | 1996-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331720-A1 | MEDIUM- OR MACRO-CYCLIC BENZYL-SUBSTITUTED HETEROCYCLE DERIVATIVES AND THEIR USES AS OREXIN-2 RECEPTOR AGONISTS | HCRTR2, HCRTR1, CRHR2 | PTGER1 1630/4885RXRA 553/4885RXRB 391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.